BAYLOR COLLEGE OF MEDICINE

Pharming Group will present 12 accepted abstracts at the 2025 ACAAI Annual Scientific Meeting in Orlando, showcasing new clinical and economic data for their rare disease portfolio.

The National Institutes of Health has awarded Baylor College of Medicine $15.6 million to fund two rare disease research consortia over five years.

Greenwich LifeSciences received European regulatory approval to expand its Phase III FLAMINGO-01 clinical trial to Ireland, adding to a global network of 150 trial sites across seven countries.

Researchers at Baylor College of Medicine discovered that metformin works directly in the brain through a previously unknown pathway involving the ventromedial hypothalamus.

Greenwich LifeSciences announced that the FDA has granted Fast Track designation for GLSI-100, an immunotherapy designed to prevent breast cancer recurrences in HLA-A*02 patients with HER2-positive breast cancer.

Baylor College of Medicine and Site Tx, Inc. have launched a multi-year collaboration to develop novel small-molecule drugs for fine-tuning immune responses across multiple diseases.

The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.

Oral testosterone undecanoate (Jatenzo) significantly improved serum testosterone levels, with 92% of men achieving levels of 450 ng/dL or higher by day 105 in the inTUne phase 3 trial.

Baylor College of Medicine and Duke University are conducting a clinical trial combining chemotherapy and immunotherapy before and after surgery for resectable mesothelioma patients, enrolling 52 participants.

The first commercial gene therapy treatments ever delivered directly to the brain in the United States have been successfully performed using ClearPoint Neuro's SmartFlow Neuro Cannula to administer KEBILIDI for AADC deficiency.